PMID: 2112100Apr 1, 1990Paper

The clinical and hormonal (C-peptide and glucagon) profile and liability to ketoacidosis during nutritional rehabilitation in Ethiopian patients with malnutrition-related diabetes mellitus

Diabetologia
Jemal AbdulkadirA S Taddesse

Abstract

Cases of malnutrition-related diabetes mellitus conforming to the description of the protein deficient pancreatic diabetes type in Ethiopian patients were compared with Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic. Fourteen of 39 malnutrition-related diabetes mellitus patients had fat malabsorption compared with only two of ten Type 1 diabetic patients and one of nine control subjects. Xylose absorption was normal favouring a pancreatic cause for the malabsorption. Plasma C-peptide during oral glucose tolerance test was significantly lower than that in Type 2 diabetic patients and normal control subjects (p less than 0.01 to 0.001) and was also consistently but not significantly higher than in Type 1 diabetic patients. Glucagon secretion patterns were similar in malnutrition-related and Type 1 diabetic patients. Of 23 new malnutrition-related diabetic patients treated with glibenclamide after nutritional rehabilitation and insulin treatment, only three responded, 14 were unresponsive but remained ketosis free for over eight days while another six developed ketoacidosis or significant ketonuria within two to six days during the trial. Sixteen unselected Type 1 diabetic patients who discontinued their in...Continue Reading

References

Aug 1, 1987·Experimental and Clinical Endocrinology·W H PetersK D Kohnert
Jan 1, 1987·Transactions of the Royal Society of Tropical Medicine and Hygiene·J AbdulkadirJ A Thompson
Nov 2, 1985·British Medical Journal·V FonsecaP Dandona
May 1, 1985·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·M M Ahuja, G P Sharma
Mar 1, 1971·The American Journal of Clinical Nutrition·R SelinusB Vahlquist
Oct 1, 1984·British Medical Bulletin·H Keen, J M Ekoe
Oct 29, 1955·Lancet·P HUGH-JONES
Jan 1, 1965·Acta paediatrica Scandinavica·G W MEEUWISSE, G DANO
Jul 1, 1965·Diabetes·B B TRIPATHY, B C KAR

❮ Previous
Next ❯

Citations

Oct 11, 2008·Diabetologia·G V GillS Tesfaye
Nov 14, 1991·Biochemical and Biophysical Research Communications·E WeitzbergJ M Lundberg
Oct 1, 1996·Diabetes Research and Clinical Practice·P DabadghaoP G Colman
Jan 1, 1997·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·N Trostler
Oct 1, 1992·Baillière's Clinical Endocrinology and Metabolism·C S Yajnik
May 23, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·A K SinghP G Colman
May 1, 1994·European Journal of Biochemistry·L Schäffer
Jul 20, 2004·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·L RossiN Gyr
Apr 1, 1992·Diabetes Research and Clinical Practice·K B HuhJ W Yoon
Mar 5, 2002·Diabetes Care·Elias S SirajCharles Faiman
Jul 25, 2020·Diabetologia·Shitaye A BalchaElisabeth R Trimble
Jun 16, 2018·Current Diabetes Reports·Shitaye Alemu BalchaElisabeth R Trimble

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.